EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

GLP-1 receptor agonists for the treatment of alcohol use disorder

Gavin N Petrie, Leah M Mayo

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci192414 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Gavin N Petrie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Alcoholism, Glucagon-Like Peptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity. These medications primarily function by enhancing insulin secretion; however, emerging evidence suggests that the effects extend beyond metabolic regulation. In this issue of the JCI , Farokhnia et al. evaluated the effects of GLP-1RAs alongside another T2D treatment, dipeptidyl peptidase-4 inhibitors (DPP-4Is), on alcohol consumption in humans and preclinical models. In humans, GLP1-RAs, but not DPP-4Is, were associated with reductions in alcohol consumption. Similarly, DPP-4 inhibition had no effect on alcohol intake in rodents. These findings invite further exploration of the mechanisms by which GLP-1RAs reduce alcohol consumption and redefine our pharmacotherapy approach to alcohol use disorder (AUD) by opening the possibility for application as an early harm-reduction tool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAlcoholismGlucagon-Like PeptidesHumansAnimalsDipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorMiceGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesGlucagon-Like Peptide 1SemaglutideGLP1R protein, human

Autor:innen und Institutionen

  • Department of Psychiatry.
  • Mathison Centre for Mental Health Education and Research, and.
  • Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

Zitieren

APA

Petrie, G. N., & Mayo, L. M. (2025). GLP-1 receptor agonists for the treatment of alcohol use disorder. Journal of Clinical Investigation. https://doi.org/10.1172/jci192414

Vancouver

Petrie GN, Mayo LM. GLP-1 receptor agonists for the treatment of alcohol use disorder. Journal of Clinical Investigation. 2025. doi:10.1172/jci192414

BibTeX
@article{Petrie2025,
  author = {Petrie, Gavin N and Mayo, Leah M},
  title = {GLP-1 receptor agonists for the treatment of alcohol use disorder},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci192414}
}
Kostenlos starten →